A new edition of the World Health Organization (WHO) Histological classification of tumours of the hypopharynx, larynx, trachea and parapharyngeal space was published in 2017. We have considered this classification regarding laryngeal neoplasms and discuss the grounds for said revision. Many of the laryngeal neoplasms described in the literature and in the previous WHO edition from 2005 have been omitted from this current revision. Many are described elsewhere in the book but it may give the new generation of pathologists/surgeons/ oncologists the false impression that these tumour entities do not exist in the larynx.
INTRODUCTION
While the crafting of a taxonomy scheme for laryngeal tumours might not seem to be so critical an endeavour, a well-constructed classification scheme actually serves as an essential foundation, allowing surgeons, pathologists and oncologists to use the same language for clarity and precision. As such, the classification of tumours is of considerable importance, and many attempts have been made to correlate the type of neoplasm with its biological behaviour. There are clinical, topographical and staging classifications and those based on the histological features of the individual neoplasms. The internationally applied TNM staging system is based on the anatomical extent of the respective tumours, but the histological features have been largely omitted. Early classifications were incomplete and too simple, only including a few types of malignant tumours, such as squamous cell carcinoma, undifferentiated carcinoma, adenocarcinoma and sarcomas.
Histological classification of laryngeal neoplasms is of essential relevance to treatment planning and evaluation of prognosis but the frequently changing terminology may lead to misunderstandings and even mistakes. The earliest tumour classification schemes relied upon the gross and/or light microscopic features of different tumour types. Presently, those classic gross and light microscopic differentiating features are being supplemented, or even replaced, by molecular features of the tumours themselves [1, 2] .
In an early attempt at standardizing the nomenclature of laryngeal tumours, the World Health Organization (WHO) published its Histological Typing of Upper Respiratory Tract Tumours (which included the larynx) in 1978 [3] . This classification was the result of a team effort by Drs. Shanmugaratnam and Sobin and pathologists from eight countries. The first version of this WHO classification is summarized in Table 1 .
The WHO classification of upper respiratory tract and ear tumours [3] was reviewed by the following experts: Table 2) .
In 2005 a third updated edition of the WHO Classification of Tumours was published, entitled Pathology and Genetics of Head and Neck Tumours [5] . The larynx was included within Chapter 3 and was entitled ''Hypopharynx, larynx and trachea'' containing the following sections (Table 3) .
A 4th edition WHO Classification of Tumours, entitled Pathology and Genetics of Head and Neck Tumours, was published in 2017 [6] . The larynx was also included in Chapter 3, now entitled ''Tumours of the hypopharynx, larynx, trachea and parapharyngeal space'' (Table 4) . 
Compliance with Ethics Guidelines
This article is based on the previously published WHO histological classifications and so does not involve any new studies of human or animal subjects performed by any of the authors.
CONSIDERATIONS
The application of immunohistochemical methods, with an ever-increasing arsenal of antibodies and recently developed molecular biology techniques, will obviously enable a more accurate identification and therefore a more reliable classification of neoplasms of the larynx. In the latest 2017 WHO Classification of Head and Neck Tumours [6] , many of the laryngeal neoplasms described in the literature have been omitted. For example, only three salivary gland tumours are described, and acinic cell, salivary duct and myoepithelial carcinomas were not included. Similarly, unusual and rare tumours, such as NUT (nuclear protein in testis) midline carcinoma, synovial sarcoma, alveolar soft sarcoma and intestinal-type adenocarcinoma, are also not listed [7] . Therefore, one has to refer to the earlier versions of the WHO Classification (2nd edition 1991 and 3rd edition ) to obtain a comprehensive view of the neoplasms that have been described in the larynx.
The histological classification is intended to facilitate the comparison of results in various fields of oncology and should be useful to pathologists, laryngologists, radiotherapists and oncologists as well as epidemiologists. A histological classification of neoplasms is extremely important for establishing a reliable prognosis, and this classification forms the foundation for appropriate clinical management of patients with laryngeal tumours.
Establishing the phenotype gives us a qualitative diagnosis of the disease. Different phenotypes have different biological behaviours, so only similar histopathological tumour types should be compared for their prognostic implications.
Specific histological types also give an indication of potential prognostic features. For example, small cell neuroendocrine carcinoma metastasizes more frequently than squamous cell carcinoma, which is in turn more aggressive than verrucous squamous cell carcinoma. These differences are further evidenced by the differing survival rates. The 5-year survival rates are approximately 68% for squamous cell carcinoma of the larynx [8] and 5% for small [9] , considering all stages of the disease. Taking squamous cell carcinoma as a yardstick for comparison, verrucous squamous cell carcinoma, low-grade mucoepidermoid carcinoma, well-differentiated neuroendocrine carcinoma and chondrosarcoma all have a more favourable prognosis, whereas poorly differentiated neuroendocrine carcinoma (both small and large cell neuroendocrine carcinoma), moderately differentiated neuroendocrine carcinoma, NUT midline carcinoma and basaloid squamous carcinoma are likely to have a less favourable outcome.
If the histological type is properly identified, then specific and personalized tumour treatment protocols can be implemented. The phenotype should therefore be considered the most important factor in determining therapeutic decisions [10, 11] . In conclusion, confirming both the histological diagnosis and clinical characteristics of every tumour will form the basis for accurate, personalized and effective treatment planning. Haematolymphoid tumours
